Product Name: p70S6K (442-449) pT444+pS447
Product Number: PE-04AGG95
Size: | 200 µg | | Price: | 65.00 |
| 1 mg | | $US | 129.00 |
Peptide Name: p70S6K (442-449) pT444+pS447
Product Use: Services as a blocking peptide for use with the p70S6K-pT444+pS447 rabbit polyclonal antibody (Cat. No.: AB-PK746) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the C-terminal third of the kinase. T444 and S447 phosphorylation stimulate phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: PR-pT-PV-pS-VK
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Scientific Background: p70S6K (RPS6KB1) is a protein-serine/threonine kinase that is a member of the AGC group of protein kinases in the RSK family, and p70 subfamily. This kinase is highly expressed and widely distributed in most tested human tissues except in the brain and spinal cord where it is more moderately expressed. It functions downstream of mTOR (FRAP1) signalling in response to growth factors to promote cell proliferation, growth, and progression through the cell cycle. p70S6K is activated by phosphorylation at T252 (by PDK1), S394 (by mTOR), T412 (by mTOR), S427, S434 (by ERK1/2), S441, T444 (by ERK1/2) and S447 (by ERK1/2). p70S6K is responsible for the phosphorylation of 40S ribosomal protein S6. It is activated by serum stimulation and this activation is inhibited by wortmannin and rapamycin. p70S6K phosphotransferase activity changes during the cell cycle, and increases 20-fold in G1 cells released from G0. It has been linked with the development of diet-induced obesity, colon adenocarcinoma and breast cancer.